Emergent BioSolutions (EBS) Misses Q4 EPS by 16c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $7.02 +4.00%
Revenue Growth %: -45.6%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -45.6%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $1.57, $0.16 worse than the analyst estimate of $1.73. Revenue for the quarter came in at $360.4 million versus the consensus estimate of $357.41 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s said to plan value strategy overhaul to revive US sales growth
- Barclays Starts Tower Semiconductor (TSEM) at Overweight
- Analysts eye Intuit investor day for signs estimates have troughed
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
